Inhibitor Therapeutics, Inc. (INTI)

0.1206 0.0000 (0.00%) At close: 11:24AM EDT

Inhibitor Therapeutics, Inc.

4905 South West Shore Blvd
Tampa, FL 33611-3329
United States
813 864 2562
https://inhibitortx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 3

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Francis E. O'Donnell Jr., M.D.	Founder, Executive Chairman & CEO	1.09M	N/A	1950
Mr. James A. McNulty CPA	Interim CFO, Treasurer & Secretary	337.96k	N/A	1950

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. It has license agreement with Johns Hopkins University. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida. Inhibitor Therapeutics, Inc is a subsidiary of Mayne Pharma Ventures Pty Ltd.

Corporate governance

Inhibitor Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.